ABT Strangle Strategy
ABT (Abbott Laboratories), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
ABT (Abbott Laboratories) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $146.00B, a trailing P/E of 23.33, a beta of 0.65 versus the broader market, a 52-week range of 81.97-139.06, average daily share volume of 13.0M, a public-listing history dating back to 1980, approximately 114K full-time employees. These structural characteristics shape how ABT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.65 indicates ABT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. ABT pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on ABT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ABT snapshot
As of May 15, 2026, spot at $84.50, ATM IV 28.79%, IV rank 65.68%, expected move 8.25%. The strangle on ABT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on ABT specifically: ABT IV at 28.79% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.25% (roughly $6.97 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABT should anchor to the underlying notional of $84.50 per share and to the trader's directional view on ABT stock.
ABT strangle setup
The ABT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABT near $84.50, the first option leg uses a $89.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABT chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $89.00 | $0.95 |
| Buy 1 | Put | $80.00 | $0.85 |
ABT strangle risk and reward
- Net Premium / Debit
- -$180.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$180.00
- Breakeven(s)
- $78.20, $90.80
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ABT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ABT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$7,819.00 |
| $18.69 | -77.9% | +$5,950.77 |
| $37.37 | -55.8% | +$4,082.54 |
| $56.06 | -33.7% | +$2,214.31 |
| $74.74 | -11.6% | +$346.08 |
| $93.42 | +10.6% | +$262.16 |
| $112.10 | +32.7% | +$2,130.39 |
| $130.79 | +54.8% | +$3,998.62 |
| $149.47 | +76.9% | +$5,866.85 |
| $168.15 | +99.0% | +$7,735.08 |
When traders use strangle on ABT
Strangles on ABT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABT chain.
ABT thesis for this strangle
The market-implied 1-standard-deviation range for ABT extends from approximately $77.53 on the downside to $91.47 on the upside. A ABT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABT IV rank near 65.68% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ABT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABT-specific events.
ABT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABT alongside the broader basket even when ABT-specific fundamentals are unchanged. Always rebuild the position from current ABT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ABT?
- A strangle on ABT is the strangle strategy applied to ABT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABT stock trading near $84.50, the strikes shown on this page are snapped to the nearest listed ABT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 28.79%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$180.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABT strangle?
- The breakeven for the ABT strangle priced on this page is roughly $78.20 and $90.80 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABT market-implied 1-standard-deviation expected move is approximately 8.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ABT?
- Strangles on ABT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABT chain.
- How does current ABT implied volatility affect this strangle?
- ABT ATM IV is at 28.79% with IV rank near 65.68%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.